Vaporox was formed to commercialize Vaporous Hyperoxia Therapy (VHT™), our patented and FDA-510(k)-cleared technology that represents a breakthrough in treating 7 different types of skin wounds, including diabetic foot ulcers (DFUs), as well as amputations, burns, frostbite, gangrene, pressure ulcers (bed sores) and skin grafts.
There are 2.1 million people in the U.S. living with an amputation, and this population is expected to double by 2050. Worldwide, annual limb amputations exceed one million.
We believe that Vaporox’s VHT technology could begin saving limbs and improving lives quickly, and with modest initial investment. In early 2019, the first VHT devices could be ready to deploy in field trials focused on healing DFU’s and pressure ulcers.